| Typicality: | 0.393 |
| Saliency: | 0.335 |
| in conjunction with therapeutic antisense oligonucleodies | 3 | other |
| chronically | 2 | manner |
| preferably | 2 | manner |
| compound → be administered to → patient | 7 |
| compound → be administered to → human | 5 |
| compound → be administered to → subject | 4 |
| negative | neutral | positive |
| 0.062 | 0.804 | 0.135 |
| Raw frequency | 16 |
| Normalized frequency | 0.335 |
| Modifier score | 0.500 |
| Perplexity | 74.806 |